UK's MHRA approves single-dose 7.2mg semaglutide (Wegovy) pen for adults with obesity
Primary care prescribers can now give the 7.2mg Wegovy weekly dose in one injection
Change
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved on 14 April 2026 a single‑dose 7.2mg semaglutide (Wegovy) pen for adults with obesity with Body Mass Index 30kg/m² or higher, enabling the maximum weekly dose to be delivered in one injection.
Why it matters
Clinicians and pharmacy teams must change prescribing and dispensing workflows to reflect a single‑dose product and its specific administration instructions. Safety monitoring teams must prioritise early reporting for patients started on the new pen via the MHRA Yellow Card scheme.
Implications
- — Primary care prescribers — must update prescribing instructions and patient counselling immediately — failure risks patient dosing errors when switching patients to the single‑dose pen.
- — Hospital and community pharmacy teams — must amend dispensing labels, instructions and staff training before dispensing the single‑dose 7.2mg pens to patients — otherwise patients may receive incorrect administration guidance at point of care.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer